Merck pens $2.1B deal with China’s SciBrunch to chase KRAS G12D

Fuente: FierceBiotech
Merck & Co. has become the latest pharma to jump on the KRAS G12D bandwagon, paying $400 million to China’s SciBrunch for a preclinical candidate.
Volver